KEVIN ALLISON: Open Payments
NPI 1477116952 · TAMPA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$33,333 in 89 payments from 12 companies in 2025. Trend: 2023 $31,007 · 2024 $12,328 · 2025 $33,333
Speaker / faculty: $17,613Consulting: $9,535Travel & lodging: $3,643Food & beverage: $2,543
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 10 | $11,279 |
| Genentech USA, Inc. | 29 | $8,768 |
| TG Therapeutics, Inc. | 14 | $6,297 |
| Amgen Inc. | 20 | $5,705 |
| E.R. Squibb & Sons, L.L.C. | 1 | $471 |
| Biogen, Inc. | 3 | $210 |
| Alexion Pharmaceuticals, Inc. | 1 | $175 |
| Novartis Pharmaceuticals Corporation | 6 | $144 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $114 |
| EMD Serono, Inc. | 2 | $75 |
Products named: Ocrevus, BRIUMVI, UPLIZNA, ULTOMIRIS, KESIMPTA, VUMERITY, ENTYVIO, ZEPOSIA.
Industry payments across FL — which companies pay providers there.
